CRISPR and Type 1 Diabetes

CRISPR technology, a powerful gene-editing tool, holds significant promise for the treatment of Type 1 Diabetes (T1D). Researchers are exploring its potential to modify or replace defective genes responsible for autoimmune attacks on insulin-producing beta cells in the pancreas. One approach involves using CRISPR to correct genetic mutations in the immune system, potentially preventing the immune response that destroys these cells. Another promising application is the use of CRISPR to enhance stem cell therapy, enabling the generation of insulin-producing cells from pluripotent stem cells. While clinical applications are still in early stages, CRISPR's ability to precisely target and edit genes offers hope for a long-term cure, rather than just symptom management, in Type 1 Diabetes.

    Related Conference of CRISPR and Type 1 Diabetes

    July 29-30, 2025

    15th World Congress on Endocrinology and Diabetes

    Paris, France
    September 08-09, 2025

    3rd World congress and Expo on Diabetes

    Frankfurt, Germany
    October 27-28, 2025

    5th World Congress on Endocrine and Diabetes

    Madrid, Spain
    October 30-31, 2025

    5th Annual Summit on Diabetes and Endocrinology

    Paris, France
    November 03-04, 2025

    34th European Diabetes Congress

    Rome, Italy
    November 06-07, 2025

    8th Annual Meeting on Diabetes and Endocrinology

    Dubai, UAE
    November 20-21, 2025

    21st World Congress on Endocrinology & Diabetes

    Paris, France
    November 24-25, 2025

    6th International conference on Diabetic complications

    Barcelona, Spain
    February 23-24, 2026

    19th International Summit on Diabetes

    London, UK
    March 26-27, 2026

    7th Global summit on Diabetes and Endocrinology

    Amsterdam, Netherlands
    May 18-19, 2026

    57th Annual Congress on Endocrinology and Diabetes Research

    Aix-en-Provence, France

    CRISPR and Type 1 Diabetes Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in